LCB84 is an ADC candidate with ADC platform technology, Trop2, licensed from an Italian biotech start-up, Mediterranea Theranostic, and recently entered phase 1/2 clinical trials in the U.S., targeting solid tumors such as breast cancer. The two companies will collaborate on the ongoing phase...
(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutica...